Activating Connexin43 gap junctions primes adipose tissue for therapeutic intervention

Area of Science:

• Metabolic research
• Adipose tissue biology
• Pharmacology

Background:

• Adipose tissue is a key target for obesity and metabolic disease treatments.
• Pharmacological agents struggle to reach adipocytes due to cell size and poor vascularization.
• Connexin43 (Cx43) gap junctions connect adipocytes, sharing limited neuronal input during cold exposure.

Purpose of the Study:

• To investigate if Cx43 gap junctions can improve the efficacy of pharmacological agents targeting adipose tissue.
• To explore the potential of Cx43-mediated adipocyte communication for enhancing metabolic treatments.

Main Methods:

• Utilized a mouse model with adipose tissue-specific Cx43 overexpression.
• Administered Cx43 activators (danegaptide) alongside metabolic drugs (Mirabegron, FGF21).
• Assessed the metabolic efficacy and adipocyte connectivity.

Main Results:

• Cx43 overexpression successfully connected adipocytes, enhancing the metabolic effects of Mirabegron and FGF21.
• Co-administration with danegaptide further augmented the efficacy of these agents.
• Demonstrated that Cx43 gap junctions prime adipose tissue for pharmacological intervention.

Conclusions:

• Connecting adipocytes via Cx43 gap junctions improves the metabolic efficacy of targeted pharmacological agents.
• Cx43 gap junction activators represent a promising strategy for combination therapies in metabolic diseases.
• This approach could overcome limitations in drug delivery to adipose tissue.